Show simple item record

AuthorMohsen, Mona O
AuthorRothen, Dominik
AuthorBalke, Ina
AuthorMartina, Byron
AuthorZeltina, Vilija
AuthorInchakalody, Varghese
AuthorGharailoo, Zahra
AuthorNasrallah, Gheyath
AuthorDermime, Said
AuthorTars, Kaspars
AuthorVogel, Monique
AuthorZeltins, Andris
AuthorBachmann, Martin F
Available date2021-09-12T06:15:40Z
Publication Date2021-08-24
Publication Namenpj Vaccines
Identifierhttp://dx.doi.org/10.1038/s41541-021-00365-w
CitationMohsen, M.O., Rothen, D., Balke, I. et al. Neutralization of MERS coronavirus through a scalable nanoparticle vaccine. npj Vaccines 6, 107 (2021). https://doi.org/10.1038/s41541-021-00365-w
URIhttp://hdl.handle.net/10576/23003
AbstractMERS-CoV continues to cause human outbreaks, so far in 27 countries worldwide following the first registered epidemic in Saudi Arabia in 2012. In this study, we produced a nanovaccine based on virus-like particles (VLPs). VLPs are safe vaccine platforms as they lack any replication-competent genetic material, and are used since many years against hepatitis B virus (HBV), hepatitis E virus (HEV) and human papilloma virus (HPV). In order to produce a vaccine that is readily scalable, we genetically fused the receptor-binding motif (RBM) of MERS-CoV spike protein into the surface of cucumber-mosaic virus VLPs. The employed CuMV-VLPs represent a new immunologically optimized vaccine platform incorporating a universal T cell epitope derived from tetanus toxin (TT). The resultant vaccine candidate (mCuMV-MERS) is a mosaic particle and consists of unmodified wild type monomers and genetically modified monomers displaying RBM, co-assembling within E. coli upon expression. mCuMV-MERS vaccine is self-adjuvanted with ssRNA, a TLR7/8 ligand which is spontaneously packaged during the bacterial expression process. The developed vaccine candidate induced high anti-RBD and anti-spike antibodies in a murine model, showing high binding avidity and an ability to completely neutralize MERS-CoV/EMC/2012 isolate, demonstrating the protective potential of the vaccine candidate for dromedaries and humans.
Languageen
PublisherSpringer Nature
SubjectNeutralization
MERS
coronavirus
nanoparticle
TitleNeutralization of MERS coronavirus through a scalable nanoparticle vaccine
TypeArticle
Issue Number107
Volume Number6
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record